Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJun 21, 2012	Agile Therapeutics to Present at the 12th European Society of Contraception and Reproductive Health Congress
Toggle SummaryJul 3, 2012	Agile Therapeutics Announces FDA Accepts New Drug Application for its Low-Dose, Once-Weekly Contraceptive Patch
Toggle SummaryJul 12, 2012	Agile Therapeutics to Present at OneMedForum New York 2012
Toggle SummaryAug 1, 2012	Agile Therapeutics Chief Medical Officer Dr. Marie Foegh Selected as one of Top 100 Healthcare Leaders by PharmaVOICE
Toggle SummaryAug 27, 2012	Agile Therapeutics Announces Three New U.S. Patents on Its Technology and the Brand Name Twirla™ for Its First Contraceptive Patch
Toggle SummarySep 20, 2012	Agile Therapeutics to Present at CBI’s Forum on Phase II-III Clinical Study Optimization
Toggle SummarySep 24, 2012	Phase III Data Show Agile Therapeutics’ Contraceptive Patch had Greater Compliance than an Oral Contraceptive
Toggle SummaryOct 16, 2012	Agile Therapeutics Commercial Head to Present at Digital Pharma East
Toggle SummaryNov 1, 2012	Phase III Data Show Greater Compliance Across Demographic Groups With Agile Therapeutics' Contraceptive Patch Compared to an Oral Contraceptive
Toggle SummaryNov 14, 2012	Agile Therapeutics Commercial Head Named Bronze Stevie Winner in the 2012 Stevie® Awards for Women in Business